单段与多段切除治疗临床IA期≤2cm非小细胞肺癌的局部复发与生存比较
该回顾性研究纳入2011-2022年接受解剖性肺段切除的临床IA期≤2cm非小细胞肺癌患者,比较单段与多段切除的肿瘤学结局。单段切除组肿瘤更小、清扫淋巴结更少、病理升级率更低,但两组的局部区域复发率和生存率无显著差异。
要点
- 单段与多段切除的局部区域复发率无显著差异(6.3% vs 7.4%,P=0.72)。
- 单段切除组病理升级率显著更低(4.2% vs 10.2%,P=0.03)。
- 两组的5年无病生存、局部无复发生存和总生存均无显著差异。
核心结论
- 对于临床IA期≤2cm的非小细胞肺癌,单段与多段切除的局部区域复发和生存无差异。
研究设计与样本
- 回顾性队列研究,使用前瞻性维护数据库,纳入2011-2022年接受解剖性肺段切除的临床IA期≤2cm非小细胞肺癌患者,排除神经内分泌肿瘤、小细胞肺癌、楔形切除或肺叶切除者。
主要发现
- 单段切除组肿瘤更小(1.3 vs 1.45 cm,P=0.02),切缘长度无显著差异(1.7 vs 2 cm,P=0.15)。
- 单段切除组清扫淋巴结更少(7 vs 10,P<0.001),病理升级率更低(4.2% vs 10.2%,P=0.03)。
- 局部区域复发率单段切除组6.3%,多段切除组7.4%(P=0.72)。
- 中位随访40个月,单段与多段切除的5年无病生存率分别为73% vs 78%,局部无复发生存率89% vs 95%,总生存率87% vs 84%。
临床怎么用
- 在临床IA期≤2cm非小细胞肺癌中,单段切除可作为多段切除的替代选择,不增加局部复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Compare oncologic outcomes between single-segment and multi-segment resections in patients with clinical stage IA1 and IA2 non-small-cell lung cancer. METHODS: A retrospective review (2011-2022) was conducted using a prospectively maintained database. Patients undergoing anatomical segmentectomy for clinical stage IA ≤2 cm non-small-cell lung cancers were included. Patients were grouped into single-segment and multi-segment resections. Patients were excluded if they had neuroendocrine tumours, small-cell lung cancer, underwent wedge resection or lobectomy. The primary outcome was locoregional recurrence. Secondary outcomes of disease-free survival, locoregional recurrence-free survival, overall survival, pathologic upstaging and perioperative complications were evaluated. RESULTS: One hundred ninety (63.8%) patients had single-segment resection and 108 (36.2%) had multi-segment resection. The single-segment resection group had smaller tumours (1.3 vs 1.45 cm, P = 0.02), but no significant difference in margin length (1.7 vs 2 cm, P = 0.15). Fewer lymph nodes were resected in single-segment resection (7 vs 10, P < 0.001), and a significantly lower rate of pathologic upstaging (4.2% vs 10.2%, P = 0.03) was observed compared with multi-segment resection. Nevertheless, locoregional recurrence developed in 6.3% of patients after single-segment resection and 7.4% patients following multi-segment resection (P = 0.72). With a median follow-up duration of 40 months, 5-year disease-free survival, locoregional recurrence-free survival and overall survival was 73, 89 and 87% following single-segment resection compared to 78, 95 and 84% after multi-segment resection. CONCLUSIONS: For patients with clinical stage IA non-small cell lung cancers ≤2 cm, locoregional recurrence and survival are not different based on whether patients receive a single-segment or multi-segment resection.
引用
- Al-Thani S, Nasar A, Villena-Vargas J, et al. All segments are created equal: locoregional recurrence and survival after single versus multi-segment resection in patients with clinical stage IA ≤2 cm non-small-cell lung cancer. Eur J Cardiothorac Surg. 2025. PMID: 40073234. doi:10.1093/ejcts/ezaf082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。